Kite keeps pressure on Novartis with CAR-T filing – pharmaphorum
pharmaphorum |
Kite keeps pressure on Novartis with CAR–T filing
pharmaphorum Kite Pharma has completed its filing for its T–cell cancer therapy with the FDA, giving rival Novartis a slender lead in the race to get the first such product to market. California-based Kite Pharma had been filing its chimeric antigen receptor T–cell … Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR–T Trial of Axicabtagene Ciloleucel in … |
